Pharmacological and clinical feature of rebamipide: new therapeutic targets

Cover Page

Cite item

Full Text

Abstract

Rebamipide is a cytoprotector developed in Japan where it has been successfully used for the treatment of stomach diseases for 30 years. Initially discovered effects of the drug included the induction of prostaglandins and the elimination of free oxygen radicals. Recent studies discovered new therapeutic targets of the drug, its new forms that made possible using rebamipid for the treatment of such diseases as NSAID enteropathy, ulcerative colitis, radiation colitis, pouchitis, enteropathy with impaired membrane digestion. It is used in endoscopy, ophthalmology, chemotherapy, rheumatology. The aim of this review is to present current information about the pharmacological and clinical feature of rebamipide and to study its therapeutic potential.

About the authors

M. Yu. Zvyaglova

Loginov Moscow Clinical Research Center

Author for correspondence.
Email: asfold@mail.ru

м.н.с. отд-ния воспалительных заболеваний кишечника

Russian Federation, Moscow

O. V. Knyazev

Loginov Moscow Clinical Research Center

Email: asfold@mail.ru

д.м.н., зав. отд-нием воспалительных заболеваний кишечника

Russian Federation, Moscow

A. I. Parfenov

Loginov Moscow Clinical Research Center

Email: asfold@mail.ru

д.м.н., проф., зав. отд. патологии кишечника

Russian Federation, Moscow

References

  1. Uchida M, Tabusa F, Komatsu M, et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-chlorobenzoylamino)-3-[2(1H)quinolinon-4-yl] propionic acid related compounds. Chem Pharm Bull. 1985;33(9):3775-86.
  2. Uchida M, Tabusa F, Komatsu M, et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. Synthesis and antiulcer activity of the metabolites of 2-(4-chlorobenzoylamino)-3-[2(1H)quinolinon-4-yl] propionic acid. Chem Pharm Bull. 1986;34(9):4821-4. doi: 10.1248/cpb.34.4821
  3. Uchida M, Tabusa F, Komatsu M, et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. Synthesis and antiulcer activity of optically active A-amino acid derivatives of 2(1H) quinolinone and oxindole. Chem Pharm Bull. 1987;35(2):853-6. doi: 10,1248/cpb.35.853
  4. Takano H, Uchida S, Kashiwagura Y, et al. Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability. Chem Pharm Bull. 2019;67(2):112-9. doi: 10.1248/cpb.c18-00629
  5. Kim KT, Lee JY, Park JH, et al. Capmul MCM/Solutol HS15-Based Microemulsion for Enhanced Oral Bioavailability of Rebamipide. J Nanosci Nanotechnol. 2017 Apr;17(4):2340-344. doi:10.1166/ jnn.2017.13314
  6. Hasegawa S, Sekino H, Matsuoka O, et al. Bioequivalence of rebamipide granules and tablets in healthy adult male volunteers. Clin Drug Investig. 2003;23:771-9. doi: 10.2165/00044011-200323120-00002
  7. Naito Y, Yoshikawa T. Rebamipide: A gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. doi: 10.1586/egh.10.25
  8. Shioya Y, Shimizu T. High-performance liquid chromatographic procedure for the determination of a new anti-gastric ulcer agent, 2-(4-chlorobenzoylamino)-3[2(1H)-quinolinon-4-yl]propionic acid, in human plasma and urine. J Chromatogr. 1988;434(1):283-7. doi: 10.1016/ 0378-4347(88)80089-6
  9. Koyama H, Sasabe G, Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002;32:573-86. doi: 10.1080/00498250210130591
  10. Arakawa T, Kobayashi K, Yoshikawa T. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9):5-13.
  11. Nishizawa T, Suzuki H, Nakagawa I, et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79(4):259-62. doi: 10,1159/000213241
  12. Suzuki T, Yoshida N, Nakabe N, et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77. doi: 10.1254/jphs.FP0071422
  13. Hashimoto K, Oshima T, Tomita T, et al. Oxidative stress induces gastric epithelial permeability through claudin-3. Biochem Biophys Res Commun. 2008;376(1):154-7. doi: 10.1016/j.bbrc.2008.08.140
  14. Gweon T, Park J, Kim B, et al; Western Kyonggi Gastrointestinal Study Group. Additive effects of Rebamipide plus proton pump inhibitors on the expression of tight junction proteins in a rat model of gastro-esophageal reflux disease. Gut Liver. 2018;12(1):46-50. doi: 10.5009/gnl17078
  15. Tarnawski A, Chai J, Pai R, et al. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49(2):202-9. doi: 10.1023/b:ddas.0000017439.60943.5c
  16. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease: A Randomised, Double-Blind, Placebo-Controlled Study. Drugs R & D. 2003;4(1):19-28. doi: 10.2165/00126839-200304010-00002
  17. Masanobu T, Tomoya T, Asano R, et al. Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins. Toxicology in Vitro. 2018;46:284-93. doi: 10.1016/j.tiv.2017.10.019
  18. Karrasch T, Steinbrecher KA, Allard B, et al. Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol. 2006;207:809-15. doi: 10.1002/jcp.20626
  19. Murata H, Yabe Y, Tsuji S, et al. Gastro-protective agent rebamipide induces cyclooxygenease-2 (COX-2) in gastric epithelial cells. Dig Dis Sci. 2005;50:S70-S75. doi: 10,1007/s10620-005-2809-0
  20. Santos MF, McCormack SA, Guo Z, et al. Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. J Clin Invest. 1997;100:216-25. doi: 10,1172/JCI119515
  21. Rao JN, Guo X, Liu L, et al. Polyamines regulate Rho-kinase and myosin phosphorylation during intestinal epithelial restitution. Am J Physiol Cell Physiol. 2003;284:848-59. doi: 10.1152/ajpcell.00371.2002
  22. Takagi T, Naito Y, Uchiyama K, et al. Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution. World J Gastroenterol. 2011;17(33):3802-9. doi: 10.3748/wjg.v17.i33.3802
  23. Talley NJ, Riff DS, Schwartz H, et al. Double-blind placebocontrolled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment Pharmacol Ther. 2001;15(10):1603-11. doi: 10.1046/j.1365-2036.2001.01074.x
  24. Miwa H, Osada T, Nagahara A, et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol. 2006;21(12):1826-31. doi: 10.1111/j.1440-1746.2006.04446.x
  25. Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci. 2008;53(11):2896-903. doi: 10,1007 / s10620-008-0255-5
  26. Du Y, Li Z, Zhan X, et al. Antiinflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008;53(11):2886-95. doi: 10,1007 / s10620-007-0180-г
  27. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Therapeutic Archive. 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
  28. Андреев Д.Н., Маев И.В., Дичева Д.Т., Самсонов А.А., Парцваниа-Виноградова Е.В. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32 [Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-Vinogradova EV. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018;90(8):27-32 (In Russ.)]. doi: 10.26442/terarkh201890827-32
  29. Terano A, Arakawa T, Sugiyama T, et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42(8):690-3. doi: 10.1007/s00535-007-2076-2
  30. Kim T, Kim E. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep. 2019;9:11696. doi: 10.1038/s41598-019-48173-6
  31. Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013;58(7):1991-2000. doi: 10.1007/s10620-013-2606-0
  32. Seo GH, Lee H. Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. Digestion. 2019;100(4):221-8. doi: 10.1159/000495288
  33. Парфенов А.И., Белостоцкий Н.И., Хомерики С.Г. и др. Ребамипид повышает активность дисахаридаз у больных энтеропатией с нарушением мембранного пищеварения. Пилотное исследование. Терапевтический архив. 2019;91(2):25-31 [Parfenov AI, Belostotsky NI, Khomeriki SG, et al. Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Therapeutic Archive. 2019;91(2):25-31 (In Russ.)]. doi: 10.26442/00403660.2019.02.000123
  34. Fujimoto A, Uraoka T, Nishizawa T, et al. Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection. Gastrointest Endosc. 2018;87(4):1114-20. doi: 10.1016/j.gie.2017.09.040
  35. Watanabe T, Takeuchi T, Handa O, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage. PLoS One. 2015;10(4):e0122330. doi: 10.1371/journal.pone.0122330
  36. Tanigawa T, Watanabe T, Otani K, et al. Rebamipide inhibits indomethacin-induced small intestinal injury: Possible involvement of intestinal microbiota modulation by upregulation of α-defensin 5. Eur J Pharmacol. 2013;704:64-9. doi: 10.1016/j.ejphar.2013.02.010
  37. Хатьков И.Е., Парфенов А.И., Князев О.В., Ручкина И.Н., Атрощенко А.О., Михайлянц Г.С. Воспалительные заболевания кишечника в прарктике терапевта и хирурга. М.: ВИТА-ПРЕСС, 2017. 120 с. [Khatkov IE, Parfenov AI, Knyazev OV, Ruchkina IN, Atroshchenko AO, Mikhailiants GS. Inflammatory bowel diseases in the practice of the therapist and surgeon: monograph. Series «Library of the doctor». Moscow: VITA-PRESS; 2017. 120 p. (In Russ.)].
  38. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL. Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol. 2000;95:1838-9. doi: 10,1111/j.1572-0241.2000.02154.x
  39. Miyata M, Kasugai K. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig Dis Sci. 2005;50 Suppl 1:S119-23. doi: 10.1007/s10620-005-2816-1
  40. Furuta R, Ando T, Watanabe O, et al. Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol. 2007;22(2):261-7. doi: 10.1111/j.1440-1746.2006.04399.x
  41. Miyata M, Konagaya T, Kakumu S, et al. Successful treatment of severe pouchitis with rebamipide refractory to antibiotics and corticosteroids: A case report. World J Gastroenterol. 2006;12(4):656-8. doi: 10.3748/wjg.v12.i4.656
  42. Matsumoto S, Tsuji K, Shirahama S. Rebamipide enema therapy for left-sided ischemic colitis patients accompanied by ulcers: Open label study. World J Gastroenterol. 2008;14(25):4059-64. doi: 10.3748/wjg.14.4059
  43. Jang H, Park S, Lee J. Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice. J Gastroenterol Hepatol. 2018;33(4):878-86. doi: 10.1111/jgh.14021
  44. Saad S, Tawfeg A. The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. J Pharmacological Research. 2000;42(1):81-6. doi: 10.1006/phrs.2000.0662
  45. Min H, Kim J. Rebamipide prevents peripheral arthritis and intestinal inflammation by reciprocally regulating Th17/Treg cell imbalance in mice with curdlan-induced spondyloarthritis. J Transl Med. 2016;14:190. doi: 10.1186/s12967-016-0942-5
  46. Sakane Y, Yamaguchi M. Retrospective Observational Study on Rebamipide Ophthalmic Suspension on Quality of Life of Dry Eye Disease Patients. J Ophthalmol. 2019;Article ID 8145731, 8 p. doi: 10.1155/2019/8145731

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies